TWI733685B - 靶向il-23a與b細胞活化因子(baff)之化合物及其用途 - Google Patents

靶向il-23a與b細胞活化因子(baff)之化合物及其用途 Download PDF

Info

Publication number
TWI733685B
TWI733685B TW105123026A TW105123026A TWI733685B TW I733685 B TWI733685 B TW I733685B TW 105123026 A TW105123026 A TW 105123026A TW 105123026 A TW105123026 A TW 105123026A TW I733685 B TWI733685 B TW I733685B
Authority
TW
Taiwan
Prior art keywords
seq
amino acid
acid sequence
polypeptide
polypeptides
Prior art date
Application number
TW105123026A
Other languages
English (en)
Chinese (zh)
Other versions
TW201712030A (zh
Inventor
珊加雅 辛
潘琦
里查瑞貝卡 貝瑞特
雷斯里Ｓ 強森
潘卡吉 朱皮塔
莎拉 羅
海霞 吳
Original Assignee
德商包林格因蓋爾漢國際股份有限公司
美商總體遺傳因子公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商包林格因蓋爾漢國際股份有限公司, 美商總體遺傳因子公司 filed Critical 德商包林格因蓋爾漢國際股份有限公司
Publication of TW201712030A publication Critical patent/TW201712030A/zh
Application granted granted Critical
Publication of TWI733685B publication Critical patent/TWI733685B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
TW105123026A 2015-07-23 2016-07-21 靶向il-23a與b細胞活化因子(baff)之化合物及其用途 TWI733685B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562196170P 2015-07-23 2015-07-23
US62/196,170 2015-07-23
US201562201067P 2015-08-04 2015-08-04
US62/201,067 2015-08-04
US201662355302P 2016-06-27 2016-06-27
US62/355,302 2016-06-27

Publications (2)

Publication Number Publication Date
TW201712030A TW201712030A (zh) 2017-04-01
TWI733685B true TWI733685B (zh) 2021-07-21

Family

ID=57835236

Family Applications (2)

Application Number Title Priority Date Filing Date
TW105123026A TWI733685B (zh) 2015-07-23 2016-07-21 靶向il-23a與b細胞活化因子(baff)之化合物及其用途
TW110122529A TWI861413B (zh) 2015-07-23 2016-07-21 靶向il-23a與b細胞活化因子(baff)之化合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110122529A TWI861413B (zh) 2015-07-23 2016-07-21 靶向il-23a與b細胞活化因子(baff)之化合物及其用途

Country Status (19)

Country Link
US (3) US10280231B2 (https=)
EP (1) EP3322436A4 (https=)
JP (1) JP6866345B2 (https=)
KR (1) KR102644875B1 (https=)
CN (1) CN108135976B (https=)
AU (1) AU2016297575B2 (https=)
CL (1) CL2018000182A1 (https=)
CO (1) CO2018001264A2 (https=)
EA (1) EA201890360A1 (https=)
IL (1) IL256665B2 (https=)
MX (1) MX2018000959A (https=)
MY (1) MY191081A (https=)
PE (1) PE20180774A1 (https=)
PH (2) PH12021552628A1 (https=)
SA (1) SA518390788B1 (https=)
SG (1) SG10201912593VA (https=)
TW (2) TWI733685B (https=)
UA (1) UA125433C2 (https=)
WO (1) WO2017015433A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI861413B (zh) * 2015-07-23 2024-11-11 德商包林格因蓋爾漢國際股份有限公司 靶向il-23a與b細胞活化因子(baff)之化合物及其用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
CN107206081A (zh) 2015-02-04 2017-09-26 勃林格殷格翰国际有限公司 治疗炎性疾病的方法
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US12577297B2 (en) 2019-09-09 2026-03-17 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibody formulations
KR20240067099A (ko) * 2021-09-30 2024-05-16 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-il23 항체 융합 단백질 및 용도
JP2026502957A (ja) * 2022-12-28 2026-01-27 スージョウ トランセンタ セラピューティクス カンパニー，リミテッド 抗ｂａｆｆ抗体を含む二重特異性結合タンパク質及びその使用
WO2025007943A1 (zh) * 2023-07-06 2025-01-09 荣昌生物制药(烟台)股份有限公司 用taci-fc融合蛋白治疗anca相关性血管炎的方法
WO2025170982A2 (en) * 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2026008004A1 (zh) * 2024-07-04 2026-01-08 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗抗磷脂综合征的方法
CN119638823A (zh) * 2024-12-10 2025-03-18 中国医学科学院病原生物学研究所 检测a35r蛋白的单克隆抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018687A1 (en) * 2010-08-02 2012-02-09 Macrogenics, Inc. Covalent diabodies and uses thereof
US20130280256A1 (en) * 2012-04-20 2013-10-24 Eli Lilly And Company Anti-baff-anti-il-17 bispecific antibodies
WO2013177101A2 (en) * 2012-05-22 2013-11-28 Bristol-Myers Squibb Company Bispecific antibodies and methods of using the same

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2001268427B2 (en) * 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
EP3479844B1 (en) 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
JP2010513245A (ja) 2006-12-14 2010-04-30 アクトジェニックス・エヌブイ 免疫調節を誘起するための結合分子の送達
EP3424951A1 (en) 2007-06-21 2019-01-09 MacroGenics, Inc. Covalent diabodies and uses thereof
BRPI0822099A2 (pt) 2007-12-21 2017-05-23 Medimmune Ltd membro de ligação isolado, uso de um membro de ligação isolado, método parav tratar um distúrbio, molécula de ácido nucléico isolada, célula hospedeira, e, método para produzir um membro de ligação
MX2010012142A (es) * 2008-05-09 2011-04-05 Abbott Gmbh & Co Kg Anticuerpos para receptor de productos finales de glucacion avanzada (rage) y usos de los mismos.
EP2376109B1 (en) 2008-12-19 2019-01-23 MacroGenics, Inc. Covalent diabodies and uses thereof
US20130129723A1 (en) * 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
GB201002238D0 (en) * 2010-02-10 2010-03-31 Affitech As Antibodies
PL3053932T3 (pl) * 2010-02-19 2021-03-08 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
EP4012714A1 (en) 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
PE20141162A1 (es) * 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
WO2012083370A1 (en) * 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
EP2686345B1 (en) * 2011-03-16 2018-04-25 Amgen Inc. Fc variants
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
CA2860600C (en) 2012-02-15 2022-07-26 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
KR102181776B1 (ko) * 2012-06-05 2020-11-24 삼성전자주식회사 범용 디바이스에서의 파일 송/수신 장치 및 방법
WO2014100490A1 (en) 2012-12-19 2014-06-26 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
JP2015088330A (ja) * 2013-10-30 2015-05-07 トヨタ自動車株式会社 硫黄含有全固体電池
WO2015100246A1 (en) * 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
WO2016039801A1 (en) * 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies
IL256665B2 (en) * 2015-07-23 2023-10-01 Boehringer Ingelheim Int IL-23A Targeting Compound and B-Cell Activating Factor Nucleic Acids Encoding Them and Use of Products Containing Them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018687A1 (en) * 2010-08-02 2012-02-09 Macrogenics, Inc. Covalent diabodies and uses thereof
US20130280256A1 (en) * 2012-04-20 2013-10-24 Eli Lilly And Company Anti-baff-anti-il-17 bispecific antibodies
WO2013177101A2 (en) * 2012-05-22 2013-11-28 Bristol-Myers Squibb Company Bispecific antibodies and methods of using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Lubberts, E. The IL-23–IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 11, 415–429 . Published:28 April 2015.
Su, Ding-Lei, et al. "Roles of pro-and anti-inflammatory cytokines in the pathogenesis of SLE." BioMed Research International 2012, p1-15
Su, Ding-Lei, et al. "Roles of pro-and anti-inflammatory cytokines in the pathogenesis of SLE." BioMed Research International 2012, p1-15 Lubberts, E. The IL-23–IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 11, 415–429 . Published:28 April 2015. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI861413B (zh) * 2015-07-23 2024-11-11 德商包林格因蓋爾漢國際股份有限公司 靶向il-23a與b細胞活化因子(baff)之化合物及其用途

Also Published As

Publication number Publication date
PE20180774A1 (es) 2018-05-07
US20210107998A1 (en) 2021-04-15
US11884744B2 (en) 2024-01-30
CL2018000182A1 (es) 2018-08-31
KR102644875B1 (ko) 2024-03-06
JP6866345B2 (ja) 2021-04-28
BR112018001255A2 (pt) 2018-09-11
EP3322436A2 (en) 2018-05-23
JP2018527323A (ja) 2018-09-20
US10844138B2 (en) 2020-11-24
UA125433C2 (uk) 2022-03-09
CN108135976A (zh) 2018-06-08
PH12018500151A1 (en) 2018-07-30
CA2993329A1 (en) 2017-01-26
US10280231B2 (en) 2019-05-07
TW201712030A (zh) 2017-04-01
MX2018000959A (es) 2018-06-06
IL256665A (en) 2018-02-28
AU2016297575A1 (en) 2018-02-15
SA518390788B1 (ar) 2021-12-26
CN108135976B (zh) 2022-10-18
EP3322436A4 (en) 2019-03-27
WO2017015433A2 (en) 2017-01-26
EA201890360A1 (ru) 2018-06-29
WO2017015433A3 (en) 2017-03-09
IL256665B2 (en) 2023-10-01
CO2018001264A2 (es) 2018-05-10
TWI861413B (zh) 2024-11-11
MY191081A (en) 2022-05-30
US20190241678A1 (en) 2019-08-08
KR20180028522A (ko) 2018-03-16
PH12021552628A1 (en) 2022-06-27
IL256665B1 (en) 2023-06-01
TW202144411A (zh) 2021-12-01
US20170022294A1 (en) 2017-01-26
SG10201912593VA (en) 2020-02-27
NZ738942A (en) 2025-05-02
NZ778160A (en) 2025-05-02
AU2016297575B2 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
TWI733685B (zh) 靶向il-23a與b細胞活化因子(baff)之化合物及其用途
US20230382988A1 (en) Compound targeting il-23a and tnf-alpha and uses thereof
ES3025557T3 (en) Antibody molecules
CA2993329C (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
EA040031B1 (ru) Соединение, нацеленное на ил-23a и фактор активации в-лимфоцитов (baff), и его применение
BR122021007560B1 (pt) Composto polipeptídico direcionado à il-23a, seu uso e composição farmacêutica
BR112018001255B1 (pt) Composto polipeptídico direcionado à il-23a, seu uso e composição farmacêutica
BR112017004169B1 (pt) Composto específico para a il23a e tnf-alfa compreendendo um primeiro polipeptídeo e um segundo polipeptídeo, e uso do mesmo
EA047781B1 (ru) Соединение, нацеленое на ил-23a и фно-альфа, и его применение
HK1240624B (en) Compound targeting il-23a and tnf-alpha and uses thereof